Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings could lead to better treatments to protect the kidney health of patients with the disease.
Lupus is an autoimmune disease that affects many different body systems, including the central nervous system, joints, skin, heart, lungs, and kidneys. Kidney involvement—termed lupus nephritis—occurs in about 50% to 75% of patients, and up to 30% of those patients develop kidney failure. Currently, experts do not understand what makes some lupus patients susceptible to lupus nephritis.
David Powell, PhD, Dawn Caster, MD, and Erik Korte, MS (University of Louisville School of Medicine) led a team that looked at the role of a particular gene that may be involved. Their previous research conducted in collaboration with investigators in Scotland revealed that mice with an inactive form of the ABIN1 protein develop lupus-like disease and have enhanced activation of the NF-kappaB pathway. This pathway is involved with the control of inflammation.
In their current study, the researchers found that mice with inactive ABIN1 develop progressive kidney problems similar to lupus nephritis in humans. The investigators then sequenced the gene encoding ABIN1 in human samples. Comparing cases of lupus with nephritis and cases of lupus without nephritis revealed strong associations of lupus nephritis with a genetic variant called rs7708392 in European Americans and a variant called rs4958881 in African Americans. Comparing cases of lupus with nephritis and healthy controls revealed a stronger association at rs7708392 in European Americans, but not at rs4958881 in African Americans.
The findings suggest that variants in the gene that encodes ABIN1 are linked with an increased risk for lupus nephritis and could be mechanistically involved in disease development through aberrant regulation of NF-kappaB.
"Our studies identify genes of the NF-kappaB pathway as a focus for future work understanding the pathogenesis and therapy of lupus nephritis," said Dr. Powell. "Understanding the role of genes in the NF-kappaB pathway in the development and severity of lupus nephritis provides the hope that personalized therapy for the condition may be possible," he added. Current treatments for lupus nephritis consist of immunosuppressive drugs, which are effective in only about 50% of patients and are associated with undesirable short- and long-term side effects.
More information: The article, entitled "ABIN1 Dysfunction as a Genetic Basis for Lupus Nephritis," will appear online on August 22, 2013, DOI: 10.1681/ASN.2013020148
Medical Xpress on facebook
Related Stories
Lupus classification system too complicated
Oct 27, 2011
The current classification system for kidney complications in patients with lupus is too detailed, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results should ...
Kidney transplants generally safe for lupus patients
Nov 02, 2009
Individuals with a history of lupus who receive a kidney transplant rarely develop the serious inflammatory condition lupus nephritis in their new organ, according to a paper being presented at the American Society of Nephrology's ...
Rituximab reduces kidney inflammation in patients with lupus
Mar 04, 2009
Treatment with the targeted drug rituximab can significantly benefit some patients with severe lupus nephritis who do not respond to conventional therapy, according to a study appearing in an upcoming issue of the Clinical Jo ...
The American College of Rheumatology issues guidelines for management of lupus nephritis
May 03, 2012
The American College of Rheumatology (ACR) has issued newly created guidelines for the screening, treatment, and management of lupus nephritis—a severe manifestation of systemic lupus erythematosus (SLE) where the disease ...
Study: Mycophenolate is superior to azathioprine as treatment for lupus nephritis
Nov 16, 2011
A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis.
Recommended for you
Exercise effective and safe in patients with moderate kidney disease
1 seconds ago
A structured exercise and lifestyle program can improve fitness, body composition, and heart function in patients with kidney disease, according to a study appearing in an upcoming issue of the Clinical Journal of the Am ...
CDC frees up drug that fights brain-eating amoeba
1 hour ago
(HealthDay)—Miltefosine, a potentially life-saving experimental drug to treat people infected with a rare but deadly brain-eating amoeba, is now available to U.S. doctors directly from the U.S. Centers ...
New device IDs disease-causing germs
2 hours ago
(HealthDay)—A new spectrometer system designed to identify 193 yeast and bacteria that are capable of making people sick has been approved by the U.S. Food and Drug Administration.
Study reveals how SARS virus hijacks host cells
4 hours ago
UC Irvine infectious disease researchers have uncovered components of the SARS coronavirus – which triggered a major outbreak of severe acute respiratory syndrome in 2002-03 – that allow it to take over host cells in ...
Myanmar must act fast to curb drug resistant TB, experts say
8 hours ago
Health officials called Thursday for urgent action to tackle "alarming" rates of drug-resistant tuberculosis in Myanmar where nearly 9,000 people catch the strain of the infectious disease each year.
FDA approves lifesaving test for tuberculosis
9 hours ago
A health scourge once considered to be largely contained in the United States has made an alarming resurgence in parts of the country. Recent tuberculosis outbreaks – including an episode in South Carolina ...
User comments
© Medical Xpress 2011-2013, Phys.org network
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings could lead to better treatments to protect the kidney health of patients with the disease.
Lupus is an autoimmune disease that affects many different body systems, including the central nervous system, joints, skin, heart, lungs, and kidneys. Kidney involvement—termed lupus nephritis—occurs in about 50% to 75% of patients, and up to 30% of those patients develop kidney failure. Currently, experts do not understand what makes some lupus patients susceptible to lupus nephritis.
David Powell, PhD, Dawn Caster, MD, and Erik Korte, MS (University of Louisville School of Medicine) led a team that looked at the role of a particular gene that may be involved. Their previous research conducted in collaboration with investigators in Scotland revealed that mice with an inactive form of the ABIN1 protein develop lupus-like disease and have enhanced activation of the NF-kappaB pathway. This pathway is involved with the control of inflammation.
In their current study, the researchers found that mice with inactive ABIN1 develop progressive kidney problems similar to lupus nephritis in humans. The investigators then sequenced the gene encoding ABIN1 in human samples. Comparing cases of lupus with nephritis and cases of lupus without nephritis revealed strong associations of lupus nephritis with a genetic variant called rs7708392 in European Americans and a variant called rs4958881 in African Americans. Comparing cases of lupus with nephritis and healthy controls revealed a stronger association at rs7708392 in European Americans, but not at rs4958881 in African Americans.
The findings suggest that variants in the gene that encodes ABIN1 are linked with an increased risk for lupus nephritis and could be mechanistically involved in disease development through aberrant regulation of NF-kappaB.
"Our studies identify genes of the NF-kappaB pathway as a focus for future work understanding the pathogenesis and therapy of lupus nephritis," said Dr. Powell. "Understanding the role of genes in the NF-kappaB pathway in the development and severity of lupus nephritis provides the hope that personalized therapy for the condition may be possible," he added. Current treatments for lupus nephritis consist of immunosuppressive drugs, which are effective in only about 50% of patients and are associated with undesirable short- and long-term side effects.
More information: The article, entitled "ABIN1 Dysfunction as a Genetic Basis for Lupus Nephritis," will appear online on August 22, 2013, DOI: 10.1681/ASN.2013020148
Medical Xpress on facebook
Related Stories
Lupus classification system too complicated
Oct 27, 2011
The current classification system for kidney complications in patients with lupus is too detailed, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results should ...
Kidney transplants generally safe for lupus patients
Nov 02, 2009
Individuals with a history of lupus who receive a kidney transplant rarely develop the serious inflammatory condition lupus nephritis in their new organ, according to a paper being presented at the American Society of Nephrology's ...
Rituximab reduces kidney inflammation in patients with lupus
Mar 04, 2009
Treatment with the targeted drug rituximab can significantly benefit some patients with severe lupus nephritis who do not respond to conventional therapy, according to a study appearing in an upcoming issue of the Clinical Jo ...
The American College of Rheumatology issues guidelines for management of lupus nephritis
May 03, 2012
The American College of Rheumatology (ACR) has issued newly created guidelines for the screening, treatment, and management of lupus nephritis—a severe manifestation of systemic lupus erythematosus (SLE) where the disease ...
Study: Mycophenolate is superior to azathioprine as treatment for lupus nephritis
Nov 16, 2011
A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis.
Recommended for you
Exercise effective and safe in patients with moderate kidney disease
1 seconds ago
A structured exercise and lifestyle program can improve fitness, body composition, and heart function in patients with kidney disease, according to a study appearing in an upcoming issue of the Clinical Journal of the Am ...
CDC frees up drug that fights brain-eating amoeba
1 hour ago
(HealthDay)—Miltefosine, a potentially life-saving experimental drug to treat people infected with a rare but deadly brain-eating amoeba, is now available to U.S. doctors directly from the U.S. Centers ...
New device IDs disease-causing germs
2 hours ago
(HealthDay)—A new spectrometer system designed to identify 193 yeast and bacteria that are capable of making people sick has been approved by the U.S. Food and Drug Administration.
Study reveals how SARS virus hijacks host cells
4 hours ago
UC Irvine infectious disease researchers have uncovered components of the SARS coronavirus – which triggered a major outbreak of severe acute respiratory syndrome in 2002-03 – that allow it to take over host cells in ...
Myanmar must act fast to curb drug resistant TB, experts say
8 hours ago
Health officials called Thursday for urgent action to tackle "alarming" rates of drug-resistant tuberculosis in Myanmar where nearly 9,000 people catch the strain of the infectious disease each year.
FDA approves lifesaving test for tuberculosis
9 hours ago
A health scourge once considered to be largely contained in the United States has made an alarming resurgence in parts of the country. Recent tuberculosis outbreaks – including an episode in South Carolina ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment